The US FDA And NIH Support Innovation in Smoking Cessation Products, Emphasizing The Need For Research On Electronic Cigarettes

The US FDA and NIH support innovation in smoking cessation products, emphasizing the need for research on electronic cigarettes

The US FDA and the National Institutes of Health (NIH) emphasized the importance of promoting innovation in smoking cessation products in a research review, and pointed out the need for in-depth research on the long-term health effects of e-cigarettes, including long-term health outcomes and toxicology studies.

According to the official website of the US Food and Drug Administration (FDA) on October 15th, in a new review published in the Annals of Internal Medicine, leaders from the National Institutes of Health (NIH) and FDA emphasized the promotion of innovative recommendations for smoking cessation treatment research and development. The authors of the article updated the regulatory approach for smoking cessation treatment and outlined innovative treatment targets, research gaps, and development opportunities. They emphasized that the active participation of clinical doctors, academia, industry, public health institutions, patient groups, and other stakeholders is crucial.

Data shows that nearly 500000 people die from smoking in the United States every year, and over 28 million adults smoke in the country each year. Although the majority of smokers express a desire to quit smoking, only 31% of those who intend to quit receive counseling or medication treatment, and the annual success rate of effective smoking cessation is less than 8%.

The reviewer proposed suggestions to address these issues, including recommendations for the FDA's 2023 Nicotine Replacement Therapy Guidelines. To stimulate innovation in the development of smoking cessation products, the author points out that in smoking cessation trials, in addition to focusing on smoking cessation, meaningful research endpoints should also be considered, such as clinically significant reductions in smoking, especially if such reductions increase the likelihood of ultimately quitting smoking.

The authors also emphasized the urgent need for further research on electronic cigarettes, including long-term health outcomes and rigorous toxicology studies. In addition, they also discussed the ongoing projects by NIH and FDA aimed at promoting innovative research on smoking cessation, which specifically include underrepresented populations in historical research trials.

This comment was released prior to the joint public meeting between the FDA and NIH on advancing smoking cessation priorities, scheduled for October 21st from 9:00 AM to 4:30 PM Eastern Time.